Gsa Capital Partners LLP Galectin Therapeutics Inc Transaction History
Gsa Capital Partners LLP
- $1.32 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding GALT
# of Institutions
93Shares Held
9.69MCall Options Held
1.16MPut Options Held
1.98M-
Vanguard Group Inc Valley Forge, PA2.13MShares$2.65 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.56MShares$1.94 Million0.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ1.18MShares$1.47 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA863KShares$1.07 Million0.0% of portfolio
-
Commonwealth Equity Services, LLC483KShares$599,2470.0% of portfolio
About GALECTIN THERAPEUTICS INC
- Ticker GALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,426,000
- Market Cap $73.7M
- Description
- Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...